DreaMed Diabetes Deploys Diabetes Data Management and Clinical Decision Support Device Into Patients’ Electronic Medical Records at Yale New Haven Health – Yahoo Finance

NEW HAVEN, Conn. & TEL AVIV, Israel, January 11, 2023–(BUSINESS WIRE)–DreaMed Diabetes, a developer of AI-based diabetes care solutions, partnered with Yale New Haven Health System (YNHHS) Center for Health Care Innovation and successfully deployed DreaMed’s endo.digital clinical decision support system as a fully integrated component of Northeast Medical Group’s (NEMG) EMR workflow. NEMG, is a not-for-profit, multispecialty medical foundation and part of YNHHS. This achievement is the first time in the industry that a diabetes clinical decision support system has been deployed as an integrated component of the patients’ electronic medical records, which allows all providers in the patients’ care continuum to provide expert-level diabetes care.
Endo.digital supports all aspects of the diabetes care pathway. This includes diabetes device data acquisition, processing patients’ diabetes data into best-in-class reporting and providing FDA cleared AI-powered personalized treatment recommendations which are clinically proven to optimize care and improve outcomes for patients with diabetes. Clinicians within NEMG have access to this powerful tool directly from the patient’s medical record by simply pressing an "endo.digital" button to seamlessly access the platform. The endo.digital system pushes critical patient information, such as glucose statistics, into the EMR flowsheet and progress notes. The patient’s approved care plan is delivered directly to the patient via the endo.digital patient app and/or email.
Lisa Stump, SVP, Chief Information and Digital Transformation Officer, YNHHS, said, "My organization deals with many technology vendors. Care for patients with diabetes adds to this challenge due to all the disparate diabetes devices required for these patients. This new technology will not only improve clinical operations but reduce the need for multiple integrations and installations by the IT team."
Eran Atlas, CEO, DreaMed Diabetes, said, "We spent the last two years listening to clinicians and health system administrators, and the feedback was clear: EMR workflow integration is a must, and providers desire one platform integrated into their workflows that allows access to all the diabetes devices data their patients utilize and processes meaningful personalized clinical decision support recommendations they can trust. We believe the solution we have deployed at Yale New Haven Health will help transform the way its clinicians provide expert-level care to their patients with diabetes."
Dr. Danielle Benaviv-Meskin, endocrinologist at NEMG said, "As an EMR integrated solution that covers most of the diabetes devices on the market, I can see an improvement to workflow efficiency in my endocrinology practice. And the inclusion of FDA-cleared decision support makes this the true one-stop-shop we have been looking for. "
About DreaMed Diabetes
DreaMed Diabetes is a medical technology company providing personalized diabetes treatment optimization solutions. The company was founded out of Schneider Children’s Medical Center of Israel, part of Clalit Health Services, in 2014. DreaMed is currently commercializing its endo.digital AI-based clinical decision support system for diabetes management. The endo.digital platform has FDA clearance for patients with Type 1 diabetes using continuous glucose monitors or self-monitoring blood glucose monitor devices and insulin pumps. The endo.digital technology also received expanded FDA clearance to include patients with Type 1 or Type 2 diabetes on multiple daily injections. For more information, please visit dreamed-diabetes.com or email ryan.hovey@dreamed.ai.
About Yale New Haven Health System
Yale New Haven Health System (YNHHS), the largest and most comprehensive healthcare system in Connecticut, is recognized for advanced clinical care, quality, service, cost effectiveness and commitment to improving the health status of the communities it serves. YNHHS includes five hospitals – Bridgeport, Greenwich, Lawrence + Memorial, Westerly and Yale New Haven hospitals, several specialty networks and Northeast Medical Group, a non-profit medical foundation with several hundred community-based and hospital-employed physicians. YNHHS is affiliated with Yale University and Yale Medicine, the clinical practice of the Yale School of Medicine and the largest academic multi-specialty practice in New England. Yale New Haven Hospital is the primary teaching hospital of Yale School of Medicine. www.ynhhs.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005743/en/
Contacts
Ryan Hovey, GM North America
(734)277-5969
Ryan.Hovey@dreamed.ai
Investors in marijuana stocks such as Aurora Cannabis (NASDAQ: ACB), Tilray (NASDAQ: TLRY), and Curaleaf (OTC: CURLF) are having a good day today — their first after four days of nonstop selling for some of these stocks. Through 12:12 p.m. ET on Wednesday, shares of Curaleaf are gaining 1.3%, and Aurora Cannabis is up 2.6%, while Tilray stock is leading the whole sector higher with a big 6% gain. The growing popularity of medical marijuana apparently is behind it all.
Yahoo Finance's Dan Howley explains why Apple is looking to move its chips and displays in-house.
Let’s take a moment to talk about opportunity, share price, and risk/reward considerations. These are some of the factors investors must consider when moving into penny stocks – and we haven’t even touched on the fundamental soundness of the company or its business model. Penny stocks – as their name suggests, they once traded for just a pennies per share, but these days are considered those equities trading at less than $5 – are a challenging market niche. The penny stock critics make valid poi
The airdrop was much awaited by the XRP community, with the project aiming to become a smart contract protocol that utilizes the XRP Ledger.
Is Pfizer stock a buy or a sell after getting a downgrade on its falling Covid-tied sales? Is PFE stock a buy or a sell right now?
In 2022, 61% of U.S. cellular customers accessed 5G networks, according to Global Wireless Solutions, a network testing and research company. Verizon says it’s got the “5G America’s been waiting for.” T-Mobile had Miley Cyrus belt out, “Faster speeds nationwiiiiiide!” Yet those tiny 5G indicators on our phones haven’t brought most of us much—except maybe a higher bill or a faster-draining battery.
One major type mostly affected male patients, while the other three mostly affected female patients, researchers said.
Nvidia's new cards usually sell out immediately. Its latest model is sitting on shelves after getting lukewarm reviews.
The memory chip markets are in severe oversupply, the worst imbalance since the financial crisis. The entire supply chain is drowning in inventory, and some manufacturers are aggressively cutting production and slowing down capital spending plans in efforts bring the situation back under control. One of those manufacturers pulling back is Micron (NASDAQ: MU).
Nvidia's (NASDAQ: NVDA) video gaming business has been in bad shape over the past year as the demand for graphics cards used in personal computers (PCs) has dropped sharply after two solid years of growth in 2020 and 2021. The chipmaker recently announced that it is bringing its RTX 4080 graphics cards to GeForce Now — Nvidia's cloud gaming service. The RTX 4080 is one of Nvidia's top-of-the-line graphics cards that brings about a huge improvement over its predecessor, the RTX 3080.
The new CEO of Karuna Therapeutics Inc. has big plans in mind for KarXT, the company's novel schizophrenia drug.
Doctors on Wednesday successfully removed two cancerous growths on the US first lady, Jill Biden, and she is now considered clear of danger, the White House physician said.All cancerous tissue was successfully removed and the margins were clear of any residual skin cancer cells," O'Connor wrote.
Today's video focuses on Advanced Micro Devices (NASDAQ: AMD) and the various new products it announced during CES 2023. While CES is mainly a trade show for the consumer market, AMD took the opportunity to showcase some exciting data center processors.
Apple (AAPL) is planning to put more of its homemade components in its devices as part of its efforts to reduce reliance on suppliers and technology partners.
My Motley Fool colleague Sean Williams even predicts that it will be the year's top-performing sector. Here are three top healthcare stocks to buy for January. Vertex also is moving forward with early-stage clinical testing of VX-522.
They're on sale right now, but also one of the more exasperating products I've tried.
The stocks for healthcare companies IQVIA Holdings (NYSE: IQV) and Vertex Pharmaceuticals (NASDAQ: VRTX), for example, have been on the upswing recently thanks to reports of increased revenues, rising earnings, and management outlooks that point to more growth on the way. IQVIA's shares were down more than 18% over the past year, but they're up more than 18% over the past three months. The company is starting to see volumes get back to normal now that the worst effects of the pandemic are fading.
The cloud computing market is developing quickly, and 2023 is an excellent time to invest in the burgeoning industry.
The talk show personality talks about why she underwent cosmetic surgery last summer
Wahl, a sports journalist, was in Qatar covering the World Cup when he died last month.

source